Myeloperoxidase in chronic kidney disease: Role of visceral fat

Tsai, Min-Sung; Shaw, Huey-Mei; Li, Yi-Jen; Lin, Meng-Te; Lee, Wen-Tsung; Chan, Khee‐Siang

doi:10.1111/nep.12187

Cited by 8 publications

(7 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Results revealed that CKD patients had significant high levels of serum MPO compared to the controls, which is similar to earlier findings (17). Increased level of serum MPO generates numerous oxygen species (OS), and these oxidants play a key role in the formation of atherosclerotic plaque and can promote cardiovascular complications (18).…”

Section: P R O V I S I O N a L L Ysupporting

confidence: 85%

Myeloperoxidase: indicator of cardiovascular disease in chronic kidney disease patients of tertiary care hospital of Karachi

et al. 2021

View full text Add to dashboard Cite

Objective: To estimate the levels of myeloperoxidase (MPO) in various stages of CKD and correlate them with inflammatory marker (CRP) and lipid profile.Methods: This cross-sectional study was conducted in the Biochemistry Department, Basic Medical Sciences Institute, Jinnah Post Graduate Medical Centre (J.P.M.C.) with collaboration of the Nephrology Department of J.P.M.C from January 2013 to September 2014. 150 participant were allocated into Group A: healthy subjects (GFR >90 ml/min/1.73m2, n=66) and Group B: CKD patients (GFR<90 ml/min/1.73m2, n=84). Serum cholesterol, triglycerides, HDL-c, CRP and myeloperoxidase were estimated. Data was presented in Mean±SD. Comparison of means within groups was performed by Mann-Whitney U test, where p-values <0.05 were considered significant.Results: With mean age of 55.64 ± 5.63 years, weight and BMI, TG, VLDL C-reactive proteins and MPO was significantly higher in in group B (p<0.001), however cholesterol and LDL-C showed no significant difference between the groups.). CRP and MPO levels demonstrated an increasing trend with decreasing GFR. Serum myeloperoxidase was found to have a significantly positive association with C-reactive protein (r = 0.710, p<0.01), cholesterol (r = 0.240, p <0.01), triglycerides (r = 0.509, p <0.01), LDL- cholesterol (r = 0.226, p <0.01) and VLDL-cholesterol (r = 0.494, p <0.01), while negative correlation with HDL- cholesterol (r= -0.370, p <0.01).Conclusion: Myeloperoxidase concentration and its relationship with lipid profile and hs-CRP in CKD patients prompts a mechanistic relationship between cardiovascular burdens in CKD patients. How ever detailed studies are required for further exploration of this link. Continuous...

show abstract

Section: P R O V I S I O N a L L Ysupporting

confidence: 85%

Myeloperoxidase: indicator of cardiovascular disease in chronic kidney disease patients of tertiary care hospital of Karachi

et al. 2021

View full text Add to dashboard Cite

show abstract

“…This is in contrast with the report of Capeillere-Blandin et al who showed a significantly higher level of myeloperoxidase in ESKD patients on hemodialysis when compared to non-dialysis CKD patients [40]. Increase in myeloperoxidase after hemodialysis [41], its differential regulation by hemodialysis membrane type [42,43], duration of dialysis, and variation in background variables such as anthropometric measures [44], comorbidities and medication use suggest their confounding rules in myeloperoxidase level [45]. The change in 3-ClY is less frequently studied in CKD.…”

Section: Discussionmentioning

confidence: 88%

Myeloperoxidase Levels and Its Product 3-Chlorotyrosine Predict Chronic Kidney Disease Severity and Associated Coronary Artery Disease

et al. 2017

View full text Add to dashboard Cite

Background: The role of myeloperoxidase in chronic kidney disease (CKD) and its association with coronary artery disease (CAD) is controversial. In this study, we compared myeloperoxidase and protein-bound 3-chlorotyrosine (ClY) levels in subjects with varying degrees of CKD and tested their associations with CAD. Methods: From Clinical Phenotyping Resource and Biobank Core, 111 patients were selected from CKD stages 1 to 5. Plasma myeloperoxidase level was measured using enzyme-linked-immunosorbent assay. Plasma protein-bound 3-ClY, a specific product of hypochlorous acid generated by myeloperoxidase was measured by liquid chromatography mass spectrometry. Results: We selected 29, 20, 24, 22, and 16 patients from stages 1 to 5 CKD, respectively. In a sex-adjusted general linear model, mean ± SD of myeloperoxidase levels decreased from 18.1 ± 12.3 pmol in stage 1 to 10.9 ± 4.7 pmol in stage 5 (p = 0.011). In patients with and without CAD, the levels were 19.1 ± 10.1 and 14.8 ± 8.7 pmol (p = 0.036). There was an increase in 3-ClY mean from 0.81 ± 0.36 mmol/mol-tyrosine in stage 1 to 1.42 ± 0.41 mmol/mol-tyrosine in stage 5 (p < 0.001). The mean 3-ClY levels in patients with and without CAD were 1.25 ± 0.44 and 1.04 ± 0.42 mmol/mol-tyrosine (p = 0.023), respectively. C-statistic of ClY when added to myeloperoxidase level to predict CKD stage 5 was 0.86, compared to 0.79 for the myeloperoxidase level alone (p = 0.0097). Conclusion: The myeloperoxidase levels decrease from stages 1 to 5, whereas activity increases. In contrast, both myeloperoxidase and ClY levels rise in the presence of CAD at various stages of CKD. Measuring both plasma myeloperoxidase and 3-CLY levels provide added value to determine the burden of myeloperoxidase-mediated oxidative stress.

show abstract

“…Recently, a ratio between myeloperoxidase (MPO) and paraoxonase 1 (PON1) was suggested as a competent indicator of HDL functionality (7). Giving that both MPO as a pro-oxidative and pro-inflammatory agent and PON1 as a powerful component of anti-oxidative defense system, are already recognized as important mediators of CKD-associated metabolic disorders (8, 9), it would be important to analyze their relationship in children with CKD and after renal transplantation, as well as their association with HDL subclasses distribution.…”

Section: Introductionmentioning

confidence: 99%

Alterations of HDL Particles in Children with End-Stage Renal Disease

Stefanović

Ristovski-Kornic

Kotur‐Stevuljević

et al. 2017

Journal of Medical Biochemistry

View full text Add to dashboard Cite

SummaryBackground: Unfavorable lipid profile presents one of most important risk factor for cardiovascular disease in renal pathology. Myeloperoxidase (MPO) as enzyme which oxidizes lipoproteins and paraoxonase1 (PON1) as anti-oxidative enzyme have been involved in pathogenesis of cardiovascular disease. In the present study we sought to assess oxidative stress status, lipoprotein subclasses distribution as well as functionality of high density lipoprotein (HDL) trough MPO/PON1 ratio in children with chronic kidney disease (CKD) and children after renal transplantation. Methods: PON1 activity and oxidative stress parameters were measured spectrophotometrically, while MPO concentration was determined using immunoassay. Separation of lipoprotein subclasses was performed by vertical gradient gel electrophoresis in 19 children with different stage of CKD and 19 post-transplantation patients (PT). Results: CKD patients had increased MPO/PON1 ratio and higher prevalence of smaller HDL subclasses when compared to PT subjects. Also, there was a significant positive correlation between MPO level and MPO/PON1 ratio with relative proportion of smaller HDL subclasses. Conclusions: Children with CKD have impaired HDL distribution that is improved after kidney transplantation. Since that measurement of HDL distribution and functionality are

show abstract

Myeloperoxidase in chronic kidney disease: Role of visceral fat

Abstract: Visceral fat predicted plasma myeloperoxidase in patients with CKD, but not in healthy controls. Myeloperoxidase was probably contributed by primed and activated neutrophils that had been irritated by visceral fat in patients with CKD.

Cited by 8 publications

References 37 publications

Myeloperoxidase: indicator of cardiovascular disease in chronic kidney disease patients of tertiary care hospital of Karachi

Myeloperoxidase: indicator of cardiovascular disease in chronic kidney disease patients of tertiary care hospital of Karachi

Myeloperoxidase Levels and Its Product 3-Chlorotyrosine Predict Chronic Kidney Disease Severity and Associated Coronary Artery Disease

Alterations of HDL Particles in Children with End-Stage Renal Disease

Contact Info

Product

Resources

About